306 related articles for article (PubMed ID: 24992319)
1. PEGylated cyclodextrins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability.
Godinho BM; Ogier JR; Quinlan A; Darcy R; Griffin BT; Cryan JF; O'Driscoll CM
Int J Pharm; 2014 Oct; 473(1-2):105-12. PubMed ID: 24992319
[TBL] [Abstract][Full Text] [Related]
2. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
3. A click chemistry route to 2-functionalised PEGylated and cationic β-cyclodextrins: co-formulation opportunities for siRNA delivery.
O'Mahony AM; Ogier J; Desgranges S; Cryan JF; Darcy R; O'Driscoll CM
Org Biomol Chem; 2012 Jul; 10(25):4954-60. PubMed ID: 22614240
[TBL] [Abstract][Full Text] [Related]
4. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.
Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD
Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
[TBL] [Abstract][Full Text] [Related]
6. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
[TBL] [Abstract][Full Text] [Related]
7. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
Ho EA; Osooly M; Strutt D; Masin D; Yang Y; Yan H; Bally M
J Pharm Sci; 2013 Jan; 102(1):227-36. PubMed ID: 23132529
[TBL] [Abstract][Full Text] [Related]
8. Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery.
Ping Y; Liu C; Zhang Z; Liu KL; Chen J; Li J
Biomaterials; 2011 Nov; 32(32):8328-41. PubMed ID: 21840593
[TBL] [Abstract][Full Text] [Related]
9. Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease.
Godinho BM; Ogier JR; Darcy R; O'Driscoll CM; Cryan JF
Mol Pharm; 2013 Feb; 10(2):640-9. PubMed ID: 23116281
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.
Lo JH; Kwon EJ; Zhang AQ; Singhal P; Bhatia SN
Bioconjug Chem; 2016 Oct; 27(10):2323-2331. PubMed ID: 27583545
[TBL] [Abstract][Full Text] [Related]
12. In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery.
O'Mahony AM; Desgranges S; Ogier J; Quinlan A; Devocelle M; Darcy R; Cryan JF; O'Driscoll CM
Pharm Res; 2013 Apr; 30(4):1086-98. PubMed ID: 23192687
[TBL] [Abstract][Full Text] [Related]
13. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.
Gao LY; Liu XY; Chen CJ; Wang JC; Feng Q; Yu MZ; Ma XF; Pei XW; Niu YJ; Qiu C; Pang WH; Zhang Q
Biomaterials; 2014 Feb; 35(6):2066-78. PubMed ID: 24315577
[TBL] [Abstract][Full Text] [Related]
14. PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo.
Aldrian G; Vaissière A; Konate K; Seisel Q; Vivès E; Fernandez F; Viguier V; Genevois C; Couillaud F; Démèné H; Aggad D; Covinhes A; Barrère-Lemaire S; Deshayes S; Boisguerin P
J Control Release; 2017 Jun; 256():79-91. PubMed ID: 28411182
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis.
Gooding M; Malhotra M; McCarthy DJ; Godinho BM; Cryan JF; Darcy R; O'Driscoll CM
Eur J Pharm Sci; 2015 Apr; 71():80-92. PubMed ID: 25703259
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes.
Buyens K; Demeester J; De Smedt SS; Sanders NN
Langmuir; 2009 May; 25(9):4886-91. PubMed ID: 19341292
[TBL] [Abstract][Full Text] [Related]
17. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
[TBL] [Abstract][Full Text] [Related]
18. PEGylated iminodiacetic acid zinc complex stabilizes cationic RNA-bearing nanoparticles.
Levy DE; Ding Z; Hu C; Zalipsky S
Bioorg Med Chem Lett; 2010 Sep; 20(18):5499-501. PubMed ID: 20696578
[TBL] [Abstract][Full Text] [Related]
19. Cationic Mucic Acid Polymer-Based siRNA Delivery Systems.
Pan DW; Davis ME
Bioconjug Chem; 2015 Aug; 26(8):1791-803. PubMed ID: 26154102
[TBL] [Abstract][Full Text] [Related]
20. Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna Delivery.
O'Mahony AM; Ogier J; Darcy R; Cryan JF; O'Driscoll CM
PLoS One; 2013; 8(6):e66413. PubMed ID: 23805220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
